GLP-1 drugs treat type 2 diabetes by mimicking a gut hormone that triggers glucose-dependent insulin release, slows digestion, and curbs appetite. Several are FDA-approved, including Ozempic, Trulicity, Victoza, Rybelsus and Byetta, plus the dual-hormone drug Mounjaro. Most lower A1C by 1 to 2 points, and several have proven heart-protective benefits in large trials.
For a broader overview, see our guide to GLP-1 treatment.
Which GLP-1 drugs are FDA-approved for type 2 diabetes?
A handful of GLP-1 receptor agonists carry FDA approval specifically to improve glycemic control in adults with type 2 diabetes. They differ in molecule, dosing frequency, and route. Mounjaro is grouped here because clinicians use it the same way, though technically it activates a second receptor in addition to GLP-1.
| Brand | Molecule | Route / frequency | First approved | Typical A1C drop |
|---|---|---|---|---|
| Byetta / Bydureon | Exenatide | Injection, twice daily / weekly | 2005 | ~0.8-1.0% |
| Victoza | Liraglutide | Injection, once daily | 2010 | ~1.1-1.5% |
| Trulicity | Dulaglutide | Injection, once weekly | 2014 | ~1.4-1.6% |
| Adlyxin | Lixisenatide | Injection, once daily | 2016 | ~0.7-0.9% |
| Ozempic | Semaglutide | Injection, once weekly | 2017 | ~1.5-1.8% |
| Rybelsus | Semaglutide | Oral, once daily | 2019 | ~1.0-1.4% |
| Mounjaro | Tirzepatide (GIP/GLP-1) | Injection, once weekly | 2022 | ~2.0-2.6% |
The brand guides for Ozempic, Trulicity, Victoza and Rybelsus cover dosing and access for each in detail.
How do GLP-1 drugs lower blood sugar?
GLP-1 receptor agonists work on several fronts at once. They stimulate the pancreas to release insulin, but only when blood glucose is elevated, which is why they rarely cause low blood sugar on their own. They suppress glucagon, the hormone that tells the liver to dump stored glucose. They slow gastric emptying so carbohydrates hit the bloodstream more gradually after a meal. And they act on appetite centers in the brain, reducing intake. Because the insulin effect is glucose-dependent, the hypoglycemia risk is far lower than with insulin or sulfonylureas unless those drugs are taken alongside.
How much do they lower A1C?
Across the pivotal trials, GLP-1 drugs reduced A1C by roughly 1 to 2 percentage points, with the newer once-weekly agents at the stronger end. Once-weekly semaglutide in the SUSTAIN program lowered A1C by about 1.5 to 1.8%. Tirzepatide, the dual GIP/GLP-1 agent, went further: in the SURPASS program it reduced A1C by up to roughly 2 to 2.6%, and in SURPASS-2 all three doses beat semaglutide 1 mg head to head. Shorter-acting agents like exenatide and lixisenatide land lower because their effect is concentrated around mealtimes rather than sustained across the day.
Which GLP-1 diabetes drugs protect the heart?
Several have dedicated cardiovascular outcome trials, and the benefit is one of the biggest reasons guidelines favor this class for higher-risk patients.
The landmark trials
- Liraglutide (LEADER) reduced the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke by about 13% versus placebo.
- Semaglutide injectable (SUSTAIN-6) cut that same composite endpoint, driven largely by fewer strokes, with a hazard ratio around 0.74.
- Dulaglutide (REWIND) showed benefit in a broad population, most of whom had cardiovascular risk factors rather than established disease.
A meta-analysis of the GLP-1 cardiovascular outcome trials put the overall reduction in major adverse cardiovascular events at roughly 14% for the class. On the strength of these data, Victoza, Trulicity, and Ozempic carry FDA indications for reducing cardiovascular risk in adults with type 2 diabetes and established heart disease.
Why do diabetes GLP-1 drugs also cause weight loss?
The same appetite suppression and delayed gastric emptying that smooth out blood sugar also reduce how much people eat, so weight loss is a built-in effect rather than a side gig. That overlap is why the identical molecules are sold under separate brands for separate uses: semaglutide is Ozempic for diabetes and Wegovy for weight, while tirzepatide is Mounjaro for diabetes and Zepbound for weight. The diabetes brands are dosed and labeled for glucose control, even though patients typically lose weight on them too.
How is a diabetes GLP-1 different from a weight-loss one?
The molecule is often identical; the differences are the approved indication, the maximum labeled dose, and what insurance will cover. Weight-management brands such as Wegovy and Zepbound are titrated to higher doses and labeled for chronic weight management, while the diabetes brands are labeled for glycemic control. Prescribing a diabetes brand purely for weight loss is off-label, and coverage rules usually follow the label. Tirzepatide blurs the line further because it adds GIP activity on top of GLP-1; the head-to-head tirzepatide versus semaglutide comparison digs into why that extra receptor matters.
Where do these drugs sit against metformin?
Metformin remains a common first step for type 2 diabetes because it is cheap, oral, and well understood. GLP-1 drugs are frequently added when metformin alone does not reach the A1C target, or chosen first for patients with cardiovascular or kidney disease who stand to gain from the proven outcome benefits. The GLP-1 versus metformin breakdown compares them on glucose control, weight, heart protection, and cost.
Do GLP-1 drugs protect the kidneys too?
Beyond glucose and the heart, semaglutide now has dedicated kidney-outcome data. The FLOW trial, published in the New England Journal of Medicine in 2024, randomized 3,533 adults with type 2 diabetes and chronic kidney disease and found that once-weekly semaglutide reduced the risk of a composite of major kidney events, cardiovascular events, and death by about 24% over a median 3.4 years, while also slowing the decline in kidney function measured by eGFR. On the strength of those results, GLP-1 drugs are increasingly favored for patients whose diabetes is complicated by kidney disease, often alongside SGLT2 inhibitors. That makes the class more than a glucose-lowering option: for higher-risk patients it carries organ-protective benefits older diabetes drugs do not.
Frequently Asked Questions
Is Mounjaro a GLP-1 drug?
Tirzepatide (Mounjaro) activates the GLP-1 receptor but also the GIP receptor, making it a dual agonist rather than a pure GLP-1 drug. Clinically it is used the same way and tends to lower A1C and weight more than single-receptor agents.
Can GLP-1 drugs replace insulin?
For some people with type 2 diabetes they reduce or delay the need for insulin, but they do not replace it for everyone, particularly in advanced disease. They are not used for type 1 diabetes.
Do they cause low blood sugar?
On their own, rarely, because the insulin effect only kicks in when glucose is high. The risk rises when they are combined with insulin or sulfonylureas, which may need dose adjustment.
Which GLP-1 lowers A1C the most?
In head-to-head data, tirzepatide produces the largest A1C reductions, followed by once-weekly semaglutide. Shorter-acting agents like exenatide and lixisenatide lower A1C less.
This article is for general education and is not medical advice. Treatment decisions for type 2 diabetes should be made with a licensed clinician.
References
- Perkovic et al., FLOW trial, New England Journal of Medicine 2024 (PubMed) — in 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg cut the primary kidney composite by 24% (HR 0.76).
- Meta-analysis of GLP-1 receptor agonist cardiovascular outcome trials (NCBI PMC) — across eight outcome trials (60,080 patients) GLP-1 RAs reduced major adverse cardiovascular events by 14% (HR 0.86).
